Journal of opioid management
-
Clinical Trial
Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
To assess the efficacy and safety of once-daily hydromorphone extended-release tablets (OROS [Alza Corporation, Mountain View, CA] hydromorphone ER) in patients with chronic neuropathic pain. ⋯ Patients with chronic neuropathic pain were safely and effectively converted to and maintained on OROS hydromorphone ER.
-
To determine what, if any, public health and societal impacts are associated specifically with injection of prescription opioids. ⋯ This study demonstrates an approach to measure the potential impact of injecting prescription opioids on public health indicators. Findings indicate a positive association between injection of prescription opioids and public health indicators suggesting a need for prescription opioid formulations that may inhibit injection of these medications.